Emerging therapies, such as sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, have shown promising results in reducing cardiovascular events, hospitalizations, and mortality in patients with HF and diabetes. This evidence concerns the gene GLP1R and hydrops fetalis.